Interestingly, prior to treatment, MDS patients showed a more favorable redox profile compared to healthy controls, as reflected by the lower ratio of oxidized glutathione (GSSG) to reduced glutathione (GSH), reduced lipid peroxidation, and higher catalase (CAT) activity. The gene discussed is CAT; the disease is myelodysplastic syndrome.